Detalhe da pesquisa
1.
CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription.
Cell
; 163(7): 1611-27, 2015 Dec 17.
Artigo
Inglês
| MEDLINE | ID: mdl-26686651
2.
ScSmOP: a universal computational pipeline for single-cell single-molecule multiomics data analysis.
Brief Bioinform
; 24(6)2023 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37779245
3.
Multiplex chromatin interactions with single-molecule precision.
Nature
; 566(7745): 558-562, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30778195
4.
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Am J Respir Crit Care Med
; 209(3): 299-306, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37890129
5.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
N Engl J Med
; 385(9): 815-825, 2021 08 26.
Artigo
Inglês
| MEDLINE | ID: mdl-34437784
6.
MCIBox: a toolkit for single-molecule multi-way chromatin interaction visualization and micro-domains identification.
Brief Bioinform
; 23(6)2022 11 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36094071
7.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Eur Respir J
; 62(6)2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37945033
8.
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
Am J Respir Crit Care Med
; 206(10): 1239-1247, 2022 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35771568
9.
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
Am J Respir Crit Care Med
; 206(11): 1361-1369, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35816621
10.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med
; 381(19): 1809-1819, 2019 11 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31697873
11.
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.
Am J Respir Crit Care Med
; 203(5): 585-593, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33023304
12.
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Am J Respir Crit Care Med
; 203(12): 1522-1532, 2021 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33734030
13.
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Thorax
; 73(8): 731-740, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29748252
14.
Pore-C simultaneously captures genome-wide multi-way chromatin interaction and associated DNA methylation status in Arabidopsis.
Plant Biotechnol J
; 20(6): 1009-1011, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35313066
15.
Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study.
Rheumatology (Oxford)
; 56(9): 1552-1559, 2017 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28595349
16.
Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.
Glomerular Dis
; 4(1): 64-73, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38600955
17.
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.
Ann Am Thorac Soc
; 20(8): 1144-1155, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36943405
18.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Lancet Respir Med
; 11(6): 550-562, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36842446
19.
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Eur J Drug Metab Pharmacokinet
; 47(6): 817-825, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36036885
20.
MCI-frcnn: A deep learning method for topological micro-domain boundary detection.
Front Cell Dev Biol
; 10: 1050769, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36531953